Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03260920
Other study ID # FTDOXY17EF
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date January 31, 2018
Est. completion date December 31, 2024

Study information

Verified date November 2023
Source Lawson Health Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety, tolerability and effects on behaviour of Syntocinon given intranasally (by a spray into the nostrils) compared to placebo (an inactive saline substance that contains no medication) in participants with frontotemporal dementia/Pick's disease. This study will take place in approximately 15 centres across Canada and the United States. Approximately 112 patients in total will be enrolled in this study. In the first phase we will examine which of three different dosing schedules of oxytocin may be more effective. In the second phase of the study, patients entering the study will be randomized to the oxytocin dosing schedule that appeared most effective in the first phase.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 112
Est. completion date December 31, 2024
Est. primary completion date June 30, 2023
Accepts healthy volunteers No
Gender All
Age group 30 Years to 80 Years
Eligibility Inclusion Criteria: - Diagnosis of probable FTD (behavioural variant FTD, FTD-semantic subtype or FTD-Progressive Nonfluent Aphasia) with supportive brain imaging (centrally rated frontotemporal atrophy score of 2 or greater on brain MRI or CT) or known FTD causing genetic mutation.68 - Current symptoms of social apathy/indifference as measured by NPI apathy/indifference severity subscale score >= 2 indicating the presence of moderate to marked levels of apathy/indifference. - Study partner who consents to study participation and who cares for/visits the patient daily for at least 3 hours/day and who can administer all trial medications. - FTLD-CDR score 0-2. - MMSE >10. - Stable baseline medications related to cognition or behaviour for >=30 days such as acetylcholinesterase inhibitors, memantine, anti-depressants, antipsychotic agents, other mood stabilizers, benzodiazepines. - Written informed consent must be obtained and documented (from the patient or, where jurisdictions allow it, from their substitute decision maker). Exclusion Criteria: - History of stroke, other neurologic or psychiatric disorder other than FTD that is considered to better account for behavioural symptoms. - History of a myocardial infarction within the last two years or congestive heart failure. - Current uncontrolled hypertension - Current bradycardia (rate < 50 beats per minute/bpm) or tachycardia (rate > 100 bpm) - Current hyponatremia (Na <135 mEq/L) - Current use of topical prostaglandin medications applied to the cervix. - Females who are pregnant or breastfeeding, or planning to conceive within the study period. - Use of any investigational or experimental drug or device within the last 60 days prior to screening or within 5 half-lives of the experimental drug, whichever is longer. - Participant has speech difficulties that in the opinion of the investigator would be incompatible with neuropsychology and safety assessments - History of cancer except: - If considered to be cured - If not being actively treated with anti-cancer therapy or radiotherapy and, in the opinion of the investigator, not likely to require treatment in the ensuing 5 years - For prostate cancer or basal cell carcinoma, no significant progression over the previous 2 years - Any clinically significant hematological, endocrine, cardiovascular, renal, hepatic, gastrointestinal or neurological disease. If the condition has been stable for at least the past year and is judged by the investigator not to interfere with the patient's participation in the study, the patient may be included. - For the CSF sub-study, current use of anticoagulant medications (warfarin, rivaroxaban, etc.). - Plan for FTD patient to be placed into long-term care or plan for hospital admission for any kind of treatment within study period or if caregiver plans for holidays/respite care > 3 days during study period.

Study Design


Intervention

Drug:
Syntocinon
Intranasal Oxytocin

Locations

Country Name City State
Canada Parkwood Institute London Ontario
Canada Montreal Neurological Institute and Hospital Montreal Quebec
Canada Laval University Quebec
Canada Sunnybrook Health Sciences Centre Toronto Ontario
Canada University Health Network Toronto Ontario
Canada University of British Columbia Vancouver British Columbia
United States Johns Hopkins Bayview Medical Center Baltimore Maryland
United States UCLA Los Angeles California
United States Columbia University Medical Center New York New York
United States University of California, San Francisco San Francisco California
United States University of Washington Seattle Washington

Sponsors (4)

Lead Sponsor Collaborator
Lawson Health Research Institute Berry Consultants, Canadian Institutes of Health Research (CIHR), Weston Brain Institute

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Neuropsychiatric Inventory (NPI) apathy/indifference domain score Pilot data from our two prior studies of oxytocin in FTD have driven the selection of the NPI as the primary outcome measure. Up to 20 weeks
Secondary Change in emotional facial expression recognition performance Up to 20 weeks
Secondary Change in the Revised Self-Monitoring Scale score Up to 20 weeks
Secondary Change in modified Clinicians Global Impression of Change (apathy) scores Up to 20 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Active, not recruiting NCT03987295 - A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) Phase 2
Withdrawn NCT05497817 - A Study to Evaluate Caregiver Connections Via Technology for Patients With Alzheimer's and Other Types of Dementia N/A
Recruiting NCT04918251 - EEG and TMS-based Biomarkers of ALS, MS and FTD
Completed NCT01002300 - Oxytocin and Social Cognition in Frontotemporal Dementia N/A
Completed NCT01890343 - Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls. Phase 2
Completed NCT00376051 - Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Phase 4
Terminated NCT00159198 - Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Phase 1
Active, not recruiting NCT04516499 - Neurofilament Surveillance Project (NSP)
Recruiting NCT04747431 - A Study of PBFT02 in Patients With Frontotemporal Dementia and Progranulin Mutations (FTD-GRN) Phase 1/Phase 2
Completed NCT03636204 - A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation Phase 1
Completed NCT01937013 - Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia Phase 2
Active, not recruiting NCT05075187 - Epidemiological Study in FRONtoTemporal Dementia
Not yet recruiting NCT05004558 - Effects of Remote-based Resistance Training on Cardiometabolic Risk Factors, Cognitive Function, and Quality of Life in Adults Living With Alzheimer's Disease and/or Related Dementias N/A
Completed NCT02999282 - Rehabilitative Trial for the Rescue of Neurophysiological Parameters in Progranulin Deficient Subjects N/A
Completed NCT00594737 - Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia Phase 3
Recruiting NCT03225144 - Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Active, not recruiting NCT04993755 - A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD Phase 2
Recruiting NCT04114994 - Longitudinal Cognitive Assessment by BoCA